Prospects and perspectives for development of a vaccine against herpes simplex virus infections

References

• Knipe DM, Howley PM, Griffin DE. Fundamental virology. Lippincott Williams & Wilkins; Philadelphia: 2001
   Google Scholar
• Dasgupta G, Chentoufi AA, Nesburn AB, et al. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccine 2009;8(8):1023-35
   PubMed Web of Science ®Google Scholar
• Chentoufi AA, BenMohamed L, Van De Perre P, Ashkar AA. Immunity to ocular and genital herpes simplex viruses infections. Clin Dev Immunol 2012;2012:732546
   Google Scholar
• Chentoufi AA, Benmohamed L. Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections. Clin Dev Immunol 2012;2012:149135
   Google Scholar
• Coleman JL, Shukla D. Recent advances in vaccine development for herpes simplex virus types I and II. Hum Vaccin Immunother 2013;9(4):729-35
   PubMed Web of Science ®Google Scholar
• Awasthi S, Huang J, Shaw C, Friedman HM. Blocking HSV-2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. J Virol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ndjamen B, Farley AH, Lee T, et al. The herpes virus Fc receptor gE-gI mediates antibody bipolar bridging to clear viral antigens from the cell surface. PLoS Pathog 2014;10(3):e1003961
   PubMed Web of Science ®Google Scholar
• Ryder N, Jin F, McNulty AM, et al. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect 2009;85(6):416-19
   PubMed Web of Science ®Google Scholar
• Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol 2012;57(5):448-62
   PubMed Web of Science ®Google Scholar
• Looker KJ, Garnett GP. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect 2005;81(2):103-7
   PubMed Web of Science ®Google Scholar
• Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years – United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010;59(15):456-9
   PubMedGoogle Scholar
• Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006;296(8):964-73
   PubMed Web of Science ®Google Scholar
• Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Postgrad Med J 2008;84(992):299-306
   PubMed Web of Science ®Google Scholar
• Kimberlin D. Herpes simplex virus, meningitis and encephalitis in neonates. Herpes 2004;11(Suppl 2):65A-76A
   Google Scholar
• Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001;108(2):223-9
   PubMed Web of Science ®Google Scholar
• Long SS, Pool TE, Vodzak J, et al. Herpes simplex virus infection in young infants during 2 decades of empiric acyclovir therapy. Pediatr Infect Dis J 2011;30(7):556-61
   PubMed Web of Science ®Google Scholar
• Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003;289(2):203-9
   PubMed Web of Science ®Google Scholar
• Arvin AM, Hensleigh PA, Prober CG, et al. Failure of antepartum maternal cultures to predict the infant’s risk of exposure to herpes simplex virus at delivery. N Engl J Med 1986;315(13):796-800
   PubMed Web of Science ®Google Scholar
• Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 2008(1):CD004946
   PubMed Web of Science ®Google Scholar
• Rouse DJ, Stringer JS. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol 2000;183(2):400-6
   PubMed Web of Science ®Google Scholar
• Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol 2003;188(3):836-43
   PubMed Web of Science ®Google Scholar
• Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006;20(1):73-83
   PubMed Web of Science ®Google Scholar
• Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002;185(1):45-52
   PubMed Web of Science ®Google Scholar
• Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362(5):427-39
   PubMed Web of Science ®Google Scholar
• Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371(9630):2109-19
   PubMed Web of Science ®Google Scholar
• Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358(15):1560-71
   PubMed Web of Science ®Google Scholar
• Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009;15(8):886-92
   PubMed Web of Science ®Google Scholar
• Jing L, Schiffer JT, Chong TM, et al. CD4 T-cell memory responses to viral infections of humans show pronounced immunodominance independent of duration or viral persistence. J Virol 2013;87(5):2617-27
   PubMed Web of Science ®Google Scholar
• Schiffer JT, Swan D, Al Sallaq R, et al. Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. Elife 2013;2:e00288
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116(3):197-202
   PubMed Web of Science ®Google Scholar
• Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342(12):844-50
   PubMed Web of Science ®Google Scholar
• Mark KE, Wald A, Magaret AS, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis 2008;198(8):1141-9
   PubMed Web of Science ®Google Scholar
• Crespi CM, Cumberland WG, Wald A, et al. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect 2007;83(5):359-64
   PubMed Web of Science ®Google Scholar
• Schiffer JT, Abu-Raddad L, Mark KE, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med 2009;1(7):7ra16
   PubMed Web of Science ®Google Scholar
• Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009;361(14):1376-85
   PubMed Web of Science ®Google Scholar
• Chentoufi AA, Kritzer E, Yu DM, et al. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol 2012;2012:187585
   PubMedGoogle Scholar
• Gantt S, Muller WJ. The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. Clin Dev Immunol 2013;2013:369172
   PubMed Web of Science ®Google Scholar
• Muller WJ, Jones CA, Koelle DM. Immunobiology of herpes simplex virus and cytomegalovirus infections of the fetus and newborn. Curr Immunol Rev 2010;6(1):38-55
   PubMedGoogle Scholar
• Connolly SA, Jackson JO, Jardetzky TS, Longnecker R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat Rev Microbiol 2011;9(5):369-81
   PubMed Web of Science ®Google Scholar
• Hummeler K, Tomassini N, Zajac B. Early events in herpes simplex virus infection: a radioautographic study. J Virol 1969;4(1):67-74
   PubMed Web of Science ®Google Scholar
• Milne RS, Nicola AV, Whitbeck JC, et al. Glycoprotein D receptor-dependent, low-pH-independent endocytic entry of herpes simplex virus type 1. J Virol 2005;79(11):6655-63
   PubMed Web of Science ®Google Scholar
• Nicola AV, McEvoy AM, Straus SE. Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells. J Virol 2003;77(9):5324-32
   PubMed Web of Science ®Google Scholar
• Clement C, Tiwari V, Scanlan PM, et al. A novel role for phagocytosis-like uptake in herpes simplex virus entry. J Cell Biol 2006;174(7):1009-21
   PubMed Web of Science ®Google Scholar
• Turner A, Bruun B, Minson T, Browne H. Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J Virol 1998;72(1):873-5
   PubMed Web of Science ®Google Scholar
• Nicola AV, Straus SE. Cellular and viral requirements for rapid endocytic entry of herpes simplex virus. J Virol 2004;78(14):7508-17
   PubMed Web of Science ®Google Scholar
• Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol 1997;136(5):1007-21
   PubMed Web of Science ®Google Scholar
• Batterson W, Furlong D, Roizman B. Molecular genetics of herpes simplex virus. VIII. further characterization of a temperature-sensitive mutant defective in release of viral DNA and in other stages of the viral reproductive cycle. J Virol 1983;45(1):397-407
   PubMed Web of Science ®Google Scholar
• Steiner I, Kennedy PG. Herpes simplex virus latent infection in the nervous system. J Neurovirol 1995;1(1):19-29
   PubMed Web of Science ®Google Scholar
• Topp KS, Meade LB, LaVail JH. Microtubule polarity in the peripheral processes of trigeminal ganglion cells: relevance for the retrograde transport of herpes simplex virus. J Neurosci 1994;14(1):318-25
   PubMed Web of Science ®Google Scholar
• McNamee EE, Taylor TJ, Knipe DM. A dominant-negative herpesvirus protein inhibits intranuclear targeting of viral proteins: effects on DNA replication and late gene expression. J Virol 2000;74(21):10122-31
   PubMed Web of Science ®Google Scholar
• Quinlan MP, Chen LB, Knipe DM. The intranuclear location of a herpes simplex virus DNA-binding protein is determined by the status of viral DNA replication. Cell 1984;36(4):857-68
   PubMed Web of Science ®Google Scholar
• Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974;14(1):8-19
   PubMed Web of Science ®Google Scholar
• Mettenleiter TC. Herpesvirus assembly and egress. J Virol 2002;76(4):1537-47
   PubMed Web of Science ®Google Scholar
• Carneiro-Sampaio M, Coutinho A. Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun 2007;75(4):1545-55
   PubMed Web of Science ®Google Scholar
• Collins WJ, Johnson DC. Herpes simplex virus gE/gI expressed in epithelial cells interferes with cell-to-cell spread. J Virol 2003;77(4):2686-95
   PubMed Web of Science ®Google Scholar
• Johnson DC, Webb M, Wisner TW, Brunetti C. Herpes simplex virus gE/gI sorts nascent virions to epithelial cell junctions, promoting virus spread. J Virol 2001;75(2):821-33
   PubMed Web of Science ®Google Scholar
• Posavad CM, Koelle DM, Shaughnessy MF, Corey L. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proc Natl Acad Sci U S A 1997;94(19):10289-94
   PubMed Web of Science ®Google Scholar
• Zuckerman RA, Limaye AP. Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) in Solid Organ Transplant Patients. Am J Transplant 2013;13(Suppl 3):55-66
   PubMedGoogle Scholar
• Koelle DM, Posavad CM, Barnum GR, et al. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest 1998;101(7):1500-8
   PubMed Web of Science ®Google Scholar
• Zhu XP, Muhammad ZS, Wang JG, et al. HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine. Viruses 2014;6(2):371-90
   PubMed Web of Science ®Google Scholar
• Halford WP. Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines? Expert Rev vaccines 2014;13(6):691-710
   PubMed Web of Science ®Google Scholar
• Dervillez X, Qureshi H, Chentoufi AA, et al. Asymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes. J Immunol 2013;191(10):5124-38
   PubMed Web of Science ®Google Scholar
• Zhu J, Peng T, Johnston C, et al. Immune surveillance by CD8alphaalpha+ skin-resident T cells in human herpes virus infection. Nature 2013;497(7450):494-7
   PubMed Web of Science ®Google Scholar
• Khodai T, Chappell D, Christy C, et al. Single and combination herpes simplex virus type 2 glycoprotein vaccines adjuvanted with CpG oligodeoxynucleotides or monophosphoryl lipid A exhibit differential immunity that is not correlated to protection in animal models. Clin Vaccine Immunol 2011;18(10):1702-9
   PubMed Web of Science ®Google Scholar
• de Veer M, Meeusen E. New developments in vaccine research – unveiling the secret of vaccine adjuvants. Discov Med 2011;12(64):195-204
   PubMed Web of Science ®Google Scholar
• Gebril A, Alsaadi M, Acevedo R, et al. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines 2012;11(9):1139-55
   PubMed Web of Science ®Google Scholar
• Dasgupta G, BenMohamed L. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine 2011;29(35):5824-36
   PubMed Web of Science ®Google Scholar
• Valencia F, Veselenak RL, Bourne N. In vivo evaluation of antiviral efficacy against genital herpes using mouse and Guinea pig models. Methods Mol Biol 2013;1030:315-26
   PubMedGoogle Scholar
• Thornton B, Griffiths JB, Walkland A. Herpes simplex vaccine using cell membrane associated antigen in an animal model. Dev Biol Stand 1981;50:201-6
   PubMedGoogle Scholar
• Hsiung GD, Mayo DR, Lucia HL, Landry ML. Genital herpes: pathogenesis and chemotherapy in the guinea pig model. Rev Infect Dis 1984;6(1):33-50
   PubMedGoogle Scholar
• Stanberry LR. Evaluation of herpes simplex virus vaccines in animals: the guinea pig vaginal model. Rev Infect Dis 1991;13(Suppl 11):S920-3
   Google Scholar
• Zaia JA, Palmer EL, Feorino PM. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus. J Infect Dis 1975;132(6):660-6
   PubMed Web of Science ®Google Scholar
• Koszinowski U, Bandlow G. Induction and in vitro demonstration of cellular immunity to DNA and RNA viruses in guinea-pigs. Clin Exp Immunol 1975;20(1):143-54
   PubMed Web of Science ®Google Scholar
• Benda R, Dbaly V. Immunogenic properties of formalin herpes antigen prepared from cell cultures. J Hyg Epidemiol Microbiol Immunol 1973;17(2):237-49
   PubMedGoogle Scholar
• Kavaklova L, Dundarov S, Andonov P, et al. Preparation and efficacy of antiherpes type 1 and 2 subunit vaccines. Acta Virol 1986;30(5):402-10
   PubMed Web of Science ®Google Scholar
• Kutinova L, Slichtova V, Vonka V. Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens. Arch Virol 1979;61(1-2):141-7
   PubMed Web of Science ®Google Scholar
• Berman PW, Gregory T, Crase D, Lasky LA. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. Science 1985;227(4693):1490-2
   PubMed Web of Science ®Google Scholar
• Berman PW, Vogt PE, Gregory T, et al. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs. J Infect Dis 1988;157(5):897-902
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Bernstein DI, Burke RL, et al. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987;155(5):914-20
   PubMed Web of Science ®Google Scholar
• Byars NE, Fraser-Smith EB, Pecyk RA, et al. Vaccinating guinea pigs with recombinant glycoprotein D of herpes simplex virus in an efficacious adjuvant formulation elicits protection against vaginal infection. Vaccine 1994;12(3):200-9
   PubMed Web of Science ®Google Scholar
• Quenelle DC, Collins DJ, Rice TL, et al. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. Antiviral Res 2008;80(2):223-4
   PubMed Web of Science ®Google Scholar
• Bourne N, Milligan GN, Stanberry LR, et al. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis 2005;192(12):2117-23
   PubMed Web of Science ®Google Scholar
• Burke RL, Goldbeck C, Ng P, et al. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 1994;170(5):1110-19
   PubMed Web of Science ®Google Scholar
• Sanchez-Pescador L, Burke RL, Ott G, Van Nest G. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine. J Immunol 1988;141(5):1720-7
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Earwood JD, Bravo FJ, et al. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 2011;29(11):2071-8
   PubMed Web of Science ®Google Scholar
• Dropulic LK, Cohen JI. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines 2012;11(12):1429-40
   PubMed Web of Science ®Google Scholar
• O’Hagan D, Goldbeck C, Ugozzoli M, et al. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 1999;17(18):2229-36
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Woolstencroft RN, Guarasci T, et al. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001;166(5):3451-7
   PubMed Web of Science ®Google Scholar
• Skoberne M, Cardin R, Lee A, et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs. J Virol 2013;87(7):3930-42
   PubMed Web of Science ®Google Scholar
• Awasthi S, Lubinski JM, Shaw CE, et al. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J Virol 2011:85(20):10472-86
   Google Scholar
• Wizel B, Persson J, Thorn K, et al. Nasal and skin delivery of IC31((R))-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine 2012;30(29):4361-8
   PubMed Web of Science ®Google Scholar
• Manservigi R, Boero A, Argnani R, et al. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. Vaccine 2005;23(7):865-72
   PubMed Web of Science ®Google Scholar
• McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine 1997;15(8):857-60
   PubMed Web of Science ®Google Scholar
• Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996;173(4):800-7
   PubMed Web of Science ®Google Scholar
• McClements WL, Armstrong ME, Keys RD, Liu MA. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci USA 1996;93(21):11414-20
   PubMed Web of Science ®Google Scholar
• Bourne N, Milligan GN, Schleiss MR, et al. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine 1996;14(13):1230-4
   PubMed Web of Science ®Google Scholar
• Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. FEMS Immunol Med Microbiol 2008;54(1):18-26
   PubMedGoogle Scholar
• Bernstein DI, Tepe ER, Mester JC, et al. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection. Vaccine 1999;17(15-16):1964-9
   PubMed Web of Science ®Google Scholar
• Shlapobersky M, Marshak JO, Dong L, et al. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 2012;93(Pt 6):1305-15
   PubMedGoogle Scholar
• Veselenak RL, Shlapobersky M, Pyles RB, et al. A Vaxfectin((R))-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012;30(49):7046-51
   PubMed Web of Science ®Google Scholar
• Bright H, Perez DL, Christy C, et al. The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27. Vaccine 2012;30(52):7529-35
   PubMed Web of Science ®Google Scholar
• Morello CS, Kraynyak KA, Levinson MS, et al. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 2012;30(46):6541-50
   PubMed Web of Science ®Google Scholar
• Nelson J, Rodriguez S, Finlayson N, et al. Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process. Hum Vaccin Immunother 2013;9(10):2211-15
   PubMed Web of Science ®Google Scholar
• Halford WP, Puschel R, Rakowski B. Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine. PLoS One 2010;5(8):e12251
   Web of Science ®Google Scholar
• Halford WP, Geltz J, Gershburg E. Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2. PLoS One 2013;8(6):e65523
   Web of Science ®Google Scholar
• Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012;491(7424):463-7
   PubMed Web of Science ®Google Scholar
• Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012;366(1):34-43
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Clement F, Vandepapeliere P, et al. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Hum Vaccin Immunother 2013;9(6):1254-62
   PubMed Web of Science ®Google Scholar
• Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002;347(21):1652-61
   PubMed Web of Science ®Google Scholar
• Safety and immunogenicity study of therapeutic HSV-2 vaccine. Available from: http://clinicaltrials.gov/show/NCT01667341
   Google Scholar
• Wald A, Koelle DM, Fife K, et al. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Vaccine 2011;29(47):8520-9
   PubMed Web of Science ®Google Scholar
• Biological efficacy study of herpv vaccine with QS-21 to treat subjects with recurrent genital herpes. Available from: http://clinicaltrials.gov/ct2/show/NCT01687595
   Google Scholar
• Study of the safety of a particular herpes vaccine in adults with or without herpes infection. Available from: http://clinicaltrials.gov/ct2/show/NCT01915212
   Google Scholar
• Da Costa X, Kramer MF, Zhu J, et al. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 2000;74(17):7963-71
   PubMed Web of Science ®Google Scholar
• Dudek T, Mathews LC, Knipe DM. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 2008;372(1):165-75
   PubMed Web of Science ®Google Scholar
• Reszka NJ, Dudek T, Knipe DM. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine 2010;28(15):2754-62
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Pesnicak L, Dowdell KC, et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008;26(32):4034-40
   PubMed Web of Science ®Google Scholar
• Hoshino Y, Pesnicak L, Dowdell KC, et al. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 2009;200(7):1088-95
   PubMed Web of Science ®Google Scholar
• McLean CS, Ni Challanain D, Duncan I, et al. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 1996;14(10):987-92
   PubMed Web of Science ®Google Scholar
• McLean CS, Erturk M, Jennings R, et al. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994;170(5):1100-9
   PubMed Web of Science ®Google Scholar
• Boursnell ME, Entwisle C, Blakeley D, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis 1997;175(1):16-25
   PubMed Web of Science ®Google Scholar
• de Bruyn G, Vargas-Cortez M, Warren T, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 2006;24(7):914-20
   PubMed Web of Science ®Google Scholar
• Posavad CM, Remington M, Mueller DE, et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010;184(6):3250-9
   PubMed Web of Science ®Google Scholar
• Dollery SJ, Delboy MG, Nicola AV. Low pH-induced conformational change in herpes simplex virus glycoprotein B. J Virol 2010;84(8):3759-66
   PubMed Web of Science ®Google Scholar
• Stampfer SD, Lou H, Cohen GH, et al. Structural basis of local, pH-dependent conformational changes in glycoprotein B from herpes simplex virus type 1. J Virol 2010;84(24):12924-33
   PubMed Web of Science ®Google Scholar
• Dasgupta G, Chentoufi AA, Kalantari M, et al. Immunodominant “asymptomatic” herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals. J Virol 2012;86(8):4358-69
   PubMed Web of Science ®Google Scholar
• Dervillez X, Gottimukkala C, Kabbara KW, et al. Future of an "asymptomatic" T-cell epitope-based therapeutic herpes simplex vaccine. Future Virol 2012;7(4):371-8
   PubMed Web of Science ®Google Scholar
• St Leger AJ, Jeon S, Hendricks RL. Broadening the repertoire of functional herpes simplex virus type 1-specific CD8+ T cells reduces viral reactivation from latency in sensory ganglia. J Immunol 2013;191(5):2258-65
   PubMed Web of Science ®Google Scholar
• Jing L, Haas J, Chong TM, et al. Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest 2012;122(2):654-73
   PubMed Web of Science ®Google Scholar
• Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2(7892):1288-90
   PubMed Web of Science ®Google Scholar
• Gershon AA, Chen J, Davis L, et al. Latency of varicella zoster virus in dorsal root, cranial, and enteric Ganglia in vaccinated children. Trans Am Clin Climatol Assoc 2012;123:17-35
   PubMedGoogle Scholar
• Abendroth A, Kinchington PR, Slobedman B. Varicella zoster virus immune evasion strategies. Curr Top Microbiol Immunol 2010;342:155-71
   PubMed Web of Science ®Google Scholar
• Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest 2011;121(12):4600-9
   PubMed Web of Science ®Google Scholar
• Safety and efficacy trial of DNA vaccines to treat genital herpes in adults. Available from: http://clinicaltrials.gov/show/NCT02030301
   Google Scholar